Effect of four different oral contraceptives on various sex hormones and serum-binding globulins

Contraception

Volumn 67, Issue 1, 2003, Pages 25-32

  Wiegratz, I ^a   Kutschera, E ^a   Lee, J H ^a   Moore, C ^b   Mellinger, U ^b   Winkler, U H ^c   Kuhl, H ^a  

^a GOETHE UNIVERSITY   (Germany)

^b BAYER PHARMA AG   (Germany)

^c Kreiskrankenhaus Wetzlar ^*  (Germany)

Author keywords

Androgens; Cycle control; Dienogest; Estradiol valerate; Ethinylestradiol; Oral contraceptives; Prolactin; Serum binding globulins

Indexed keywords

DIENOGEST PLUS ESTRADIOL VALERATE PLUS ETHINYLESTRADIOL; DIENOGEST PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; LEIOS; ORAL CONTRACEPTIVE AGENT; PRASTERONE SULFATE; PROLACTIN; SERUM GLOBULIN; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; THYROXINE BINDING GLOBULIN; TRANSCORTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLEEDING; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; NORMAL HUMAN; ORAL CONTRACEPTION; PROLACTIN RELEASE; PROTEIN BLOOD LEVEL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL; DEHYDROEPIANDROSTERONE SULFATE; DOUBLE-BLIND METHOD; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; GONADAL STEROID HORMONES; HUMANS; LEVONORGESTREL; NANDROLONE; REFERENCE VALUES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; THYROXINE-BINDING PROTEINS; TREATMENT OUTCOME;

EID: 0037232892     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(02)00436-5     Document Type: Article

References (39)

1. Larsson-Cohn U., Fahraeus L., Wallentin L., Zador G. Effects of the estrogenicity of levonorgestrel/ethinylestradiol combinations on the lipoprotein status. Acta Obstet Gynecol Scand. 105:(Suppl):1982;S37-S40.
2. Dunn N., Thorogood M., Faragher B., de Caestecker L., MacDonald T.M., McCollum C., Thomas S., Mann R. Oral contraceptives and myocardial infarction results of the MICA case-control study . Br Med J. 318:1999;1579-1584.
3. Moore D.E., Kawagoe S., Davajan V., Nakamura R.M., Mishell D.R. An in vivo system in man for quantitation of estrogenicity. II. Pharmacologic changes in binding capacity of serum corticosteroid-binding globulin induced by conjugated estrogens, mestranol, and ethinyl estradiol. Am J Obstet Gynecol. 130:1978;482-486.
4. Song S., Chen J.K., He M.L., Fotherby K. Effect of some oral contraceptives on serum concentrations of sex hormone binding globulin and ceruloplasmin. Contraception. 39:1989;385-399.
5. Gurpide E., Marks C. Influence of endometrial 17β-hydroxysteroid dehydrogenase activity on the binding of estradiol to receptors. J Clin Endocrinol Metab. 52:1981;252-255.
6. Moore C., Elger W., Graeser T., Hoffmann H., Schwarz S., Zimmermann H. Different alternatives for the substitution of ethinylestradiol in oral contraceptives. Kuhl H., Nikolov R. Re-evaluation of contraceptive steroids. 1998;25-35 Harfe Verlag, Bad Blankenburg.
7. Hoffmann H., Moore C., Zimmermann H., et al. Approaches to the replacement of ethinylestradiol by natural 17β-estradiol in combined oral contraceptives. Exp Toxic Pathol. 50:1998;458-464.
8. Kuhl H. Ideal dose of ethinylestradiol. Elstein M. Extragenital effects of oral contraceptives. 1997;27-38 Parthenon, Carnforth.
9. Kuhl H. The clinical relevance of different progestins in oral contraceptives. Kuhl H., Nikolov R. Re-evaluation of contraceptive steroids. 1998;13-24 Harfe Verlag, Bad Blankenburg.
10. Gruschke A., Kuhl H. Validity of radioimmunological methods for determining free testosterone in serum. Fertil Steril. 76:2001;576-582.
11. Serup J., Bostofte E., Larsen S., Westergaard J. Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. Acta Obstet Gynecol Scand. 60:1981;203-206.
12. Hirvonen E., Allonen H., Anttila M., et al. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas. 21:1995;27-32.
13. Csemiczky G., Dieben T., Coeling Bennink H.J., Landgren B.M. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17β-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days. Contraception. 54:1996;333-338.
14. Fraser I.S., Hickey M. Endometrial vascular changes and bleeding disturbances with long-acting progestins. Steroids. 65:2000;665-670.
15. Jung-Hoffmann C., Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol. 156:1987;199-203.
16. Refn H., Kjaer A., Lebech A.M., Borggaard B., Schierup L. Clinical and hormonal effects of two oral contraceptives correlations to serum concentrations of levonorgestrel and gestodene . Contraception. 41:1990;259-268.
17. van der Vange N., Blankenstein M.A., Kloosterboer H.J., Haspels A.A., Thijssen J.H.H. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception. 41:1990;345-351.
18. Wiegratz I., Jung-Hoffmann, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception. 51:1995;341-346.
19. Coenen C.M.H., Thomas C.M.G., Borm G.F., Hollanders J.M.G., Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 53:1996;171-176.
20. Jung-Hoffmann C., Fitzner M., Kuhl H. Oral contraceptives containing 20 or 30 μg ethinylestradiol and 150 μg desogestrel pharmacokinetics and pharmacodynamic parameters . Horm Res. 36:1991;238-246.
21. Jung-Hoffmann C., Heidt F., Kuhl H. Effect of two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel upon various hormonal parameters. Contraception. 38:1988;593-603.
22. Schwartz U., Hammerstein J. The oestrogenic potency of various contraceptive steroids as determined by their effects on transcortin binding capacity. Acta Endocrinol. 76:1974;159-171.
23. Hammond G.L., Langley M.S., Robinson P.A., Nummi S., Lund L. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel and levonorgestrel. Fertil Steril. 42:1984;44-51.
24. Jung-Hoffmann C., Storch A., Kuhl H. Serum concentrations of ethinylestradiol, 3-keto-desogestrel, SHBG, CBG and gonadotropins during treatment with a biphasic oral contraceptive containing desogestrel. Horm Res. 38:1992;184-189.
25. Kuhl H., Jung-Hoffmann C., Weber J., Boehm B.O. The effect of a biphasic desogestrel-containing oral contraceptive on carbohydrate metabolism and various hormonal parameters. Contraception. 47:1993;55-68.
26. Ain K.B., Mori Y., Refetoff S. Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation a mechanism for estrogen-induced elevation of serum TBG concentration . J Clin Endocrinol Metab. 65:1987;689-696.
27. Dunn J.F., Nisula B.C., Rodbard S. Transport of steroid hormones binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma . J Clin Endocrinol Metab. 53:1981;58-68.
28. Gaspard U.J., Romus M.A., Gillain D., Franchimont P., Duvivier J. Plasma hormone levels in women receiving new oral contraceptives containing ethinylestradiol plus levonorgestrel and desogestrel. Contraception. 27:1983;577-590.
29. Gaspard U.J., Dubois M., Gillain D., Duvivier J., Demey-Ponsart E., Franchimont P. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Contraception. 29:1984;305-318.
30. Kuhnz W., Baumann A., Staks T., Dippelt L., Knuppen R., Jütting G. Pharmakokinetics of gestodene and ethinylestradiol in 14 women in three months of treatment with a new tri-step combination oral contraceptive serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum . Contraception. 48:1993;303-322.
31. Kim-Börklund T., Landgren B.M., Hamberger L. Is the contraceptive effect of 300 μg norethisterone mainly peripheral or central? Contraception. 45:1992;57-66.
32. Aden U., Jung-Hoffmann C., Kuhl H. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. Contraception. 58:1998;75-81.
33. Fern M., Rose D.P., Fern E.B. Effect of oral contraceptives on plasma androgenic steroids and their precursors. Obstet Gynecol. 51:1978;541-544.
34. Kuhl H., Gahn G., Romberg G., März W., Taubert H.-D. A randomized cross-over comparison of two low dose oral contraceptives upon hormonal and metabolic parameters. I. Effects upon sexual hormone levels. Contraception. 31:1985;583-593.
35. Gaspard U.J., Romus M.A., Gillain D., Duvivier J., Demey-Ponsart E., Franchimont P. Plasma hormone levels in women receiving new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Contraception. 27:1983;577-590.
36. Davis J.R.E., Selby C., Jeffcoate C. Oral contraceptive agent do not affect serum prolactin in normal women. Clin Endocrinol. 20:1984;427-434.
37. Luciano A.A., Sherman B.M., Chapler F.K., Hauser K.S., Wallace R.B. Hyperprolactinemia and contraception a prospective study . Obstet Gynecol. 63:1985;506-510.
38. Abu-Fadil S., DeVane G., Siler T.M., Yen S.S.C. Effects of oral contraceptive steroids on pituitary prolactin secretion. Contraception. 13:1976;79-85.
39. Dericks-Tan J.S.E., Taubert H.D. Elevation of serum prolactin during application of oral contraceptives. Contraception. 14:1976;1-8.